title: Reply to P. Niravath et Al.
authors.affiliation: Centre de Recherche, Centre Hospitalier Universitaire de Québec, Québec, Canada elizabeth.maunsell@uresp.ulaval.ca.
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Maunsell
authors.affiliation: Los Angeles Biomedical Research Institute at the Harbor-UCLA Medical Centre, Torrance, CA.
authors.forename: Rowan T
authors.initials: RT
authors.lastname: Chlebowski
authors.affiliation: Mayo Clinic, Rochester, MN.
authors.forename: James N
authors.initials: JN
authors.lastname: Ingle
authors.affiliation: NCIC Clinical Trials Group, Kingston, Ontario, Canada.
authors.forename: Harriet
authors.initials: H
authors.lastname: Richardson
authors.affiliation: Massachusetts General Hospital, Boston, MA.
authors.forename: Paul E
authors.initials: PE
authors.lastname: Goss
mesh_terms: D000730:Androstadienes / Q000627:therapeutic use*; D047072:Aromatase Inhibitors / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000517:prevention & control*; D005260:Female; D006801:Humans; D011788:Quality of Life
chemical_list: D000730:Androstadienes; D047072:Aromatase Inhibitors